Pharmacology Medication Table PDF

Pharmacology Made Easy Medication Information Table Monoclonal Antibody Against RANKL – denosumab Category Information THERAPEUTIC USE Treatment of osteoporosis for...

Pharmacology Made Easy Medication Information Table Monoclonal Antibody Against RANKL – denosumab Category Information THERAPEUTIC USE Treatment of osteoporosis for clients who are postmenopausal. Clients assigned male at birth who are at high risk for osteoporosis. Clients who are at increased risk for fractures or osteoporosis related to long-term glucocorticoid therapy. Binds receptor activator of nuclear factor kappa-b ligand (RANKL) to decrease the ability of osteocytes to produce and activate osteoclasts. ADVERSE DRUG Hypocalcemia, osteonecrosis of the jaw, atypical femur fractures, and REACTIONS musculoskeletal pain. Common adverse effects: upper respiratory infections, hypertension, headaches, and diarrhea. INTERVENTIONS Pre-existing hypocalcemia should be resolved before starting medication. Ensure client is taking daily calcium and vitamin D supplements. May cause harm to a fetus. Perform pregnancy testing for clients who can become pregnant before initiating therapy. ADMINISTRATION 60 mg subcutaneous injection every 6 months. Discard the medication if solution is cloudy. CLIENT INSTRUCTIONS Take supplemental calcium and vitamin D. Perform weight-bearing exercises, such as walking. Practice good oral hygiene and report to their provider jaw pain or loose teeth. Inform their dentist that they are taking denosumab. Report manifestations of hypocalcemia (muscle cramps, numbness or tingling). CONTRAINDICATIONS Active infection PRECAUTIONS Chronic infections or whose history included serious or opportunistic infections. Adjusted for clients who have severe kidney disease INTERACTIONS Immunosuppressant medications increase the risk for serious infections. Copyright ©2023 Assessment Technologies Institute, L.L.C. All rights reserved. This resource is copyright protected material of ATI and is provided for use solely under license by ATI. Copying, distributing, or posting this material on the internet or social media is strictly prohibited. Posting on institution LMS requires ATI’s prior written permission.  PAGE 1 www.atitesting.com ©2023 Assessment Technologies Institute, L.L.C.